Lead asset shows systemic, dose‑dependent anti‑tumour activity

US study marks company’s second clinical trial of ovarian cancer therapy

Clesrovimab is first monoclonal antibody offering a single fixed dose for infants

Greater flexibility for people with systemic lupus erythematosus

Company expects two‑year dfs data by q1 2028

New authorisation offers additional option for patients with lvef ≥40%

Partnership to develop next‑generation T‑cell engagers for solid tumours

First patient dosed as DOMISOL study grows beyond Australia

Subcutaneous delivery shows IV‑level efficacy in moderate to severe TED

Study expands development of the antibody into hepatocellular carcinoma